Schizophrenia in 2020: Trends in diagnosis and therapy

Psychiatry and Clinical Neurosciences

Volumn 69, Issue 11, 2015, Pages 661-673

  Gaebel, Wolfgang ^a,b,c   Zielasek, Jürgen ^a,b  

^a Department of Orthopedic Surgery   (Germany)

^b WHO Collaborating Center for Quality Assurance and Empowerment in Mental Health   (Germany)

^c Orthopadische Klin Dusseldorf   (Germany)

Author keywords

classification; etiopathogenesis; psychoses; psychotic disorders; schizophrenia

Indexed keywords

NEUROLEPTIC AGENT;

BRAIN DYSFUNCTION; CLINICAL PRACTICE; DISEASE CLASSIFICATION; EARLY DIAGNOSIS; FAMILY; GENETIC ASSOCIATION; HUMAN; MATHEMATICAL ANALYSIS; MENTAL PATIENT; NEGATIVE SYNDROME; NEUROIMAGING; PATHOGENESIS; PSYCHOTHERAPY; REVIEW; SCHIZOPHRENIA; TRANSCRANIAL MAGNETIC STIMULATION; TRENDS;

ANTIPSYCHOTIC AGENTS; HUMANS; PSYCHOTHERAPY; SCHIZOPHRENIA;

EID: 84945470750     PISSN: 13231316     EISSN: 14401819     Source Type: Journal    
DOI: 10.1111/pcn.12322     Document Type: Review

References (59)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th edn. American Psychiatric Publishing, Arlington, WA, 2013.
2. Tandon R, Gaebel W, Barch DM, et al. Definition and description of schizophrenia in the DSM-5. Schizophr. Res. 2013; 150: 3-10.
3. Gaebel W, Zielasek J, Cleveland HR,. Classifying psychosis-challenges and opportunities. Int. Rev. Psychiatry 2012; 24: 538-548.
4. Gaebel W, Zielasek J, Cleveland HR,. Psychotic disorders in ICD-11. Asian J. Psychiatr. 2013; 6: 263-265.
5. Nordgaard J, Arnfred SM, Handest P, Parnas J,. The diagnostic status of first-rank symptoms. Schizophr. Bull. 2008; 34: 137-154.
6. Wilson JE, Niu K, Nicolson SE, Levine SZ, Heckers S,. The diagnostic criteria and structure of catatonia. Schizophr. Res. 2015; 164: 256-262.
7. Tsuang MT, Van Os J, Tandon R, et al. Attenuated psychosis syndrome in DSM-5. Schizophr. Res. 2013; 150: 31-35.
8. Schultze-Lutter F, Michel C, Ruhrmann S, Schimmelmann BG,. Prevalence and clinical significance of DSM-5-attenuated psychosis syndrome in adolescents and young adults in the general population: The Bern Epidemiological At-Risk (BEAR) study. Schizophr. Bull. 2014; 40: 1499-1508.
9. Chen C, Cheng L, Grennan K, et al. Two gene co-expression modules differentiate psychotics and controls. Mol. Psychiatry 2013; 18: 1308-1314.
10. Hiroi N, Takahashi T, Hishimoto A, Izumi T, Boku S, Hiramoto T,. Copy number variation at 22q11.2: From rare variants to common mechanisms of developmental neuropsychiatric disorders. Mol. Psychiatry 2013; 18: 1153-1165.
11. Ripke S, O'Dushlaine C, Chambert K, et al. Genome-wide association analysis identifies 13 new risk loci for schizophrenia. Nat. Genet. 2013; 45: 1150-1159.
12. Schwab SG, Wildenauer DB,. Genetics of psychiatric disorders in the GWAS era: An update on schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 2013; 263 (Suppl. 2): S147-S154.
13. Xu B, Ionita-Laza I, Roos JL, et al. De novo gene mutations highlight patterns of genetic and neural complexity in schizophrenia. Nat. Genet. 2012; 44: 1365-1369.
14. Deakin J, Lennox BR, Zandi MS,. Antibodies to the N-methyl-D-aspartate receptor and other synaptic proteins in psychosis. Biol. Psychiatry 2014; 75: 284-291.
15. Needham E, Zandi MS,. Recent advances in the neuroimmunology of cell-surface CNS autoantibody syndromes, Alzheimer's disease, traumatic brain injury and schizophrenia. J. Neurol. 2014; 261: 2037-2042.
16. Zandi MS, Deakin JB, Morris K, et al. Immunotherapy for patients with acute psychosis and serum N-Methyl D-Aspartate receptor (NMDAR) antibodies: A description of a treated case series. Schizophr. Res. 2014; 160: 193-195.
17. Howes OD, Kapur S,. A neurobiological hypothesis for the classification of schizophrenia: Type A (hyperdopaminergic) and type B (normodopaminergic). Br. J. Psychiatry 2014; 205: 1-3.
18. Wijtenburg SA, Yang S, Fischer BA, Rowland LM,. In vivo assessment of neurotransmitters and modulators with magnetic resonance spectroscopy: Application to schizophrenia. Neurosci. Biobehav. Rev. 2015; 51C: 276-295.
19. Deco G, Kringelbach ML,. Great expectations: Using whole-brain computational connectomics for understanding neuropsychiatric disorders. Neuron 2014; 84: 892-905.
20. Zielasek J, Gaebel W,. Modern modularity and the road towards a modular psychiatry. Eur. Arch. Psychiatry Clin. Neurosci. 2008; 258 (Suppl. 5): 60-65.
21. Fornito A, Zalesky A, Breakspear M,. The connectomics of brain disorders. Nat. Rev. Neurosci. 2015; 16: 159-172.
22. Winton-Brown TT, Fusar-Poli P, Ungless MA, Howes OD,. Dopaminergic basis of salience dysregulation in psychosis. Trends Neurosci. 2014; 37: 85-94.
23. Garety PA, Freeman D,. The past and future of delusions research: From the inexplicable to the treatable. Br. J. Psychiatry 2013; 203: 327-333.
24. Eifler S, Rausch F, Schirmbeck F, et al. Neurocognitive capabilities modulate the integration of evidence in schizophrenia. Psychiatry Res. 2014; 219: 72-78.
25. Castellani CA, Melka MG, Diehl EJ, Laufer BI, O'Reilly RL, Singh SM,. DNA methylation in psychosis: Insights into aetiology and treatment. Epigenomics 2015; 7: 67-74.
26. Akdeniz C, Tost H, Meyer-Lindenberg A,. The neurobiology of social environmental risk for schizophrenia: An evolving research field. Soc. Psychiatry Psychiatr. Epidemiol. 2014; 49: 507-517.
27. Haddad L, Schäfer A, Streit F, et al. Brain structure correlates of urban upbringing, an environmental risk factor for schizophrenia. Schizophr. Bull. 2015; 41: 115-122.
28. Allardyce J, Gaebel W, Zielasek J, van Os J,. Deconstructing Psychosis conference February 2006: The validity of schizophrenia and alternative approaches to the classification of psychosis. Schizophr. Bull. 2007; 33: 863-867.
29. Braff DL, Freedman R, Schork NJ, Gottesman II,. Deconstructing schizophrenia: An overview of the use of endophenotypes in order to understand a complex disorder. Schizophr. Bull. 2007; 33: 21-32.
30. Pickard BS,. Schizophrenia biomarkers: Translating the descriptive into the diagnostic. J. Psychopharmacol. 2015; 29: 138-143.
31. Morris SE, Cuthbert BN,. Research Domain Criteria: Cognitive systems, neural circuits, and dimensions of behavior. Dialogues Clin. Neurosci. 2012; 14: 29-37.
32. Badcock JC, Hugdahl K,. A synthesis of evidence on inhibitory control and auditory hallucinations based on the Research Domain Criteria (RDoC) framework. Front. Hum. Neurosci. 2014; 8: 180.
33. Ford JM, Morris SE, Hoffman RE, et al. Studying hallucinations within the NIMH RDoC framework. Schizophr. Bull. 2014; 40 (Suppl. 4): S295-S304.
34. Owen MJ,. New approaches to psychiatric diagnostic classification. Neuron 2014; 84: 564-571.
35. Saha S, Chant D, McGrath J,. A systematic review of mortality in schizophrenia: Is the differential mortality gap worsening over time? Arch. Gen. Psychiatry 2007; 64: 1123-1131.
36. Anthes E,. Live faster, die younger. Nature 2014; 508: S16-S17.
37. Cullen BA, McGinty EE, Zhang Y, et al. Guideline-concordant antipsychotic use and mortality in schizophrenia. Schizophr. Bull. 2013; 39: 1159-1168.
38. Sarin F, Wallin L,. Cognitive model and cognitive behavior therapy for schizophrenia: An overview. Nord. J. Psychiatry 2014; 68: 145-153.
39. Dunlop J, Brandon NJ,. Schizophrenia drug discovery and development in an evolving era: Are new drug targets fulfilling expectations? J. Psychopharmacol. 2015; 29: 230-238.
40. Choi DW, Armitage R, Brady LS, et al. Medicines for the mind: Policy-based 'pull' incentives for creating breakthrough CNS drugs. Neuron 2014; 84: 554-563.
41. Pankevich DE, Altevogt BM, Dunlop J, Gage FH, Hyman SE,. Improving and accelerating drug development for nervous system disorders. Neuron 2014; 84: 546-553.
42. Huhn M, Tardy M, Spineli LM, et al. Efficacy of pharmacotherapy and psychotherapy for adult psychiatric disorders: A systematic overview of meta-analyses. JAMA Psychiatry 2014; 71: 706-715.
43. Thomas N, Hayward M, Peters E, et al. Psychological therapies for auditory hallucinations (voices): Current status and key directions for future research. Schizophr. Bull. 2014; 40 (Suppl. 4): S202-S212.
44. Drusch K, Stroth S, Kamp D, Frommann N, Wölwer W,. Effects of Training of Affect Recognition on the recognition and visual exploration of emotional faces in schizophrenia. Schizophr. Res. 2014; 159: 485-490.
45. Hovington CL, McGirr A, Lepage M, Berlim MT,. Repetitive transcranial magnetic stimulation (rTMS) for treating major depression and schizophrenia: A systematic review of recent meta-analyses. Ann. Med. 2013; 45: 308-321.
46. Wobrock T, Guse B, Cordes J, et al. Left prefrontal high-frequency repetitive transcranial magnetic stimulation for the treatment of schizophrenia with predominant negative symptoms: A sham-controlled, randomized multicenter trial. Biol. Psychiatry 2015; 77: 978-988.
47. Wölwer W, Lowe A, Brinkmeyer J, et al. Repetitive transcranial magnetic stimulation (rTMS) improves facial affect recognition in schizophrenia. Brain Stimul. 2014; 7: 559-563.
48. Slotema CW, Blom JD, van Lutterveld R, Hoek HW, Sommer IE,. Review of the efficacy of transcranial magnetic stimulation for auditory verbal hallucinations. Biol. Psychiatry 2014; 76: 101-110.
49. Gaebel W, Muijen M, Baumann AE, et al. EPA guidance on building trust in mental health services. Eur. Psychiatry 2014; 29: 83-100.
50. Gaebel W, Zielasek J,. Overcoming stigmatizing attitudes towards psychiatrists and psychiatry. Acta Psychiatr. Scand. 2015; 131: 5-7.
51. Gaebel W, Riesbeck M, Wobrock T,. Schizophrenia guidelines across the world: A selective review and comparison. Int. Rev. Psychiatry 2011; 23: 379-387.
52. Miller AL, Crismon ML, Rush AJ, et al. The Texas medication algorithm project: Clinical results for schizophrenia. Schizophr. Bull. 2004; 30: 627-647.
53. Weinmann S, Hoerger S, Erath M, Kilian R, Gaebel W, Becker T,. Implementation of a schizophrenia practice guideline: Clinical results. J. Clin. Psychiatry 2008; 69: 1299-1306.
54. Kohn R, Saxena S, Levav I, Saraceno B,. The treatment gap in mental health care. Bull. WHO 2004; 82: 858-866.
55. Barker-Haliski M, Friedman D, White HS, French JA,. How clinical development can, and should, inform translational science. Neuron 2014; 84: 582-593.
56. Koutsouleris N, Riecher-Rössler A, et al. Detecting the psychosis prodrome across high-risk populations using neuroanatomical biomarkers. Schizophr. Bull. 2015; 41: 471-482.
57. Kahn RS, Sommer IE,. The neurobiology and treatment of first-episode schizophrenia. Mol. Psychiatry 2015; 20: 84-97.
58. Krystal JH, State MW,. Psychiatric disorders: Diagnosis to therapy. Cell 2014; 157: 201-214.
59. Schubert CR, Xi HS, Wendland JR, O'Donnell P,. Translating human genetics into novel treatment targets for schizophrenia. Neuron 2014; 84: 537-541.